Mr. Tom Tamberrino is a seasoned leader with a distinguished career in sales and marketing leadership, business development, and executive management, with much of his success rooted in the U.S. healthcare industry. He brings a wealth of experience, including a history of entrepreneurial ventures and significant contributions to the medical technology sector. Prior to joining Profound Medical, Mr. Tamberrino served as Vice President of Sales and Marketing at Novadaq Technologies Inc. for several years. Under his leadership, Novadaq established itself as the market leader in near-infrared fluorescence imaging, achieving remarkable growth and driving revenues from an annual run rate of $27 million in 2012 to over $82 million in 2017. This growth culminated in Novadaq’s acquisition by Stryker Corporation for approximately $701 million, after which Mr. Tamberrino continued with Stryker until 2018 to support the integration of Novadaq’s business. Earlier in his career, Mr. Tamberrino held progressive sales management positions at LifeCell Corporation, eventually serving as Area Director. During his time at LifeCell Corporation, he led a 50-person sales team across the Northeastern U.S. and Canada, marketing regenerative tissue matrices. Mr. Tamberrino holds a Bachelor of Science degree in Marketing with a Minor in Psychology from Georgetown University and a Master of Business Administration from Emory University.
Intraoperative MRI (iMRI) is rapidly emerging as a transformative platform for real-time, image-guided therapy, bringing together advanced imaging, innovative devices, and precision treatment technologies. This panel will explore how collaboration among Cook Medical, Siemens Healthineers, and Profound Medical is enabling physicians to visualize, guide, adapt, and confirm therapy in real time, improving procedural precision and patient outcomes. Through perspectives from industry leaders and a pioneering interventional radiologist, attendees will gain insight into the technical, clinical, and commercial factors accelerating iMRI adoption and shaping the future of image-guided therapy.